Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 19,16 € (+112,42 %). Medianen er 17,75 € (+96,78 %).
| Køb |
10 |
| Behold |
2 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Immunic advances vidofludimus calcium toward Phase 3 readouts, expects data by year-end
Immunic said its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS remain on track to deliver top-line data by the end of 2026, with a potential US NDA submission in mid-2027 and a regulatory decision targeted for 2028 if results are positive. The company plans to start a Phase 3 program in progressive MS later this year following supportive Phase 2 CALLIPER analyses. In Q2, operating expenses rose to $35.3 million and net loss widened to about $34.1 million; cash and equivalents totaled $155.1 million, which management expects to fund operations into late 2027. Immunic also strengthened its leadership and board ahead of potential commercialization. » Mere på finance.yahoo.com
Virksomhedstal
| (EUR) | juni 2026 | |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | 0 | - |
| Nettoresultat | -29,88 mio. | 31,30 % |
| EBITDA | -29,79 mio. | 31,13 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 134,7 mio. € |
Antal aktier | 13,62 mio. |
Højeste/laveste i 52 uger | 15,09 € - 4,38 € |
| Udbytte | Nej |
Beta | 1,41 |
P/E (PE Ratio) | -2,38 |
PEG (PEG Ratio) | -0,03 |
K/I (PB Ratio) | 3,81 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
| Navn | Immunic |
| CEO | Erik Lundgren |
| Medarbejdere | 100 |
